AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03709277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-Driven Intervention
Description: The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
Study NCT01329276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Symbicort® forte Turbohaler®
Description: 320 µg budesonide / 9 µg formoterol fumarate dihydrate
Study NCT01329276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Symbicort® forte Turbohaler®
Description: 320 µg budesonide / 9 µg formoterol fumarate dihydrate
Study NCT00054327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
Study NCT00054327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00054327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00054327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo total body irradiation
Study NCT00054327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: infusion
Study NCT00054327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transfusion
Study NCT01956097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HX106 590mg
Study NCT01956097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HX106 1180mg
Study NCT01956097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02745678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thermosensitive gel rectal formulation
Study NCT02231892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: HAC coil (real rTMS or sham rTMS)
Study NCT02231892 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: HAC coil (real rTMS or sham rTMS)
Study NCT02024360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: 16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
Study NCT02117960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 4 cap 1 g Omega-3 per day for 2 months
Study NCT00656266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
Study NCT00656266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo medication
Description: medication that looks like mycophenolate mofetil
Study NCT03532100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:4 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
Study NCT03532100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:3 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
Study NCT03532100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:2 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
Study NCT02117960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cap 1 g Placebo(paraffin) per day for 2 months
Study NCT02180724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (ACP-196)
Study NCT01897350 — intervention group
Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Study NCT01748708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy
Description: 100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
Study NCT01748708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
Study NCT02475343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schiotz tonometer
Description: The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No training, assessed within 60 mins
Description: Subjects receive no training in resuscitation
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra-brief video; assessed in 60 mins
Description: Subjects receive an ultra-brief (90-second) video on hands-only CPR
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video; assessed in 60 mins
Description: Subjects receive a brief (5-minute) video on hands-only CPR
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video + hands-on; ass'd in 60 mins
Description: Subjects receive a brief (5-minute) video with hands-on manikin practice
Study NCT03477968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DDimer test
Description: Measuring the level of DDimer in blood sample
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra-brief video; assessed at 2 months
Description: Subjects see ultra-brief video (90-seconds), are assessed two months later
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video; assessed 2 months later
Description: Subjects see brief video (5 minutes), are then assessed two months later
Study NCT01191736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video + hands-on; ass'd 2 ms later
Description: Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
Study NCT01979666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitrate patch
Description: patients in the study group will get a nitrate patch
Study NCT01979666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: control group patients will get a placebo patch
Study NCT01979666 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI scan
Description: MRI scan after 6 weeks of treatment
Study NCT01979666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan after 6 weeks of treatment
Study NCT04104191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-1000AF System
Description: The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
Study NCT03402204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Study NCT03402204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Study NCT04251897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel support surface
Description: This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
Study NCT04251897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel support surface
Description: This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
Study NCT06552949 — intervention group
Intervention type: PROCEDURE
Intervention: Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)
Description: Emergent conventional laparoscopic cholecystectomy
Study NCT01114971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
Study NCT02077218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo cardiac CT
Study NCT02077218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of blood samples
Study NCT02077218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02077218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02329938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein tension free reair
Description: a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
Study NCT02329938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Desarda's repair
Description: the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
Study NCT00764686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Education
Description: One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
Study NCT00764686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Education
Description: Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
Study NCT02332837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A: Questionnaire accuracy
Description: Participants will be tested by questionnaire to measure how well consent is understood
Study NCT02332837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B: Questionnaire speed of completion
Description: Time to complete questionnaire from time of presentation
Study NCT02332837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C: Questionnaire Completion rate
Description: Number of participants who complete the questionnaire
Study NCT04480710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRV431 75mg
Description: 1 x 75mg softgel capsule
Study NCT04480710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (1 softgel)
Description: 1 x placebo softgel capsule
Study NCT04480710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRV431 225mg
Description: 3 x 75mg softgel capsule
Study NCT04480710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (3 softgels)
Description: 3 x placebo softgel capsule
Study NCT03079635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
Study NCT03079635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
Study NCT04349943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition therapy
Description: With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
Study NCT03443271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block with Bupivicaine
Description: Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
Study NCT03443271 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block with Placebo drug
Description: Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
Study NCT01114971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
Study NCT01114971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
Study NCT01114971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
Study NCT01114971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)
Study NCT01127607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisdexamfetamine
Description: 3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
Study NCT01127607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Description: 3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
Study NCT00633568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
Description: Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
Study NCT00633568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
Description: Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
Study NCT05451706 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
Study NCT05451706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
Study NCT05451706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental help-seeking self-persuasion
Description: Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
Study NCT03119181 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tymbion Lidocaine/epinephrine solution
Description: The external ear canal will be filled with Tymbion drug solution
Study NCT03119181 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution
Description: The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
Study NCT02399540 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham
Study NCT02399540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Paired tDCS
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
Study NCT02399540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Unpaired tDCS
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
Study NCT02399540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Late LTP-like Plasticity tDCS
Description: Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
Study NCT01208961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanova (4 g) and Lovaza (4 g)
Description: Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
Study NCT01208961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza (4 g) and Epanova (4 g)
Description: Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
Study NCT03321123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
Study NCT02285790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy
Study NCT02285790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsy